BidaskClub downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a strong sell rating in a research report released on Wednesday.

LXRX has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a strong-buy rating to a hold rating in a report on Wednesday, November 7th. ValuEngine lowered shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 17th. Cowen reiterated a hold rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Gabelli reiterated a hold rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Finally, Citigroup cut their price objective on shares of Lexicon Pharmaceuticals from $27.00 to $26.00 and set a buy rating on the stock in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $25.25.

Shares of LXRX stock opened at $7.11 on Wednesday. Lexicon Pharmaceuticals has a 12 month low of $7.04 and a 12 month high of $13.97. The company has a current ratio of 2.90, a quick ratio of 2.83 and a debt-to-equity ratio of 8.85. The firm has a market capitalization of $778.55 million, a price-to-earnings ratio of -5.60 and a beta of 0.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The firm had revenue of $6.90 million for the quarter, compared to analyst estimates of $12.56 million. During the same quarter in the previous year, the business posted ($0.29) EPS. The firm’s revenue was down 74.3% compared to the same quarter last year. Sell-side analysts forecast that Lexicon Pharmaceuticals will post -1.29 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in LXRX. Schwab Charles Investment Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,061 shares of the biopharmaceutical company’s stock worth $2,893,000 after purchasing an additional 14,426 shares during the last quarter. BlackRock Inc. increased its position in shares of Lexicon Pharmaceuticals by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock worth $53,066,000 after purchasing an additional 195,461 shares during the last quarter. Tocqueville Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $164,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $205,000. Finally, Northern Trust Corp increased its position in shares of Lexicon Pharmaceuticals by 2.1% in the 2nd quarter. Northern Trust Corp now owns 584,393 shares of the biopharmaceutical company’s stock worth $7,013,000 after purchasing an additional 12,289 shares during the last quarter.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: Why is insider trading harmful?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.